Week 87 on Ozempic: separating real results from TikTok mythology

What's this video probably claiming?

At week 87, @theangiegrams is almost certainly sharing a long-term weight loss update on semaglutide (brand name Ozempic, approved for type 2 diabetes, though frequently used off-label for weight management). Week 87 puts this creator well past the one-year mark, which means the video is likely covering plateau experiences, dose adjustments, side effect management, or total weight lost to date. Long-running series like this tend to include personal metrics, commentary on hunger suppression, and comparisons to earlier weeks. There may also be discussion of cost, insurance coverage, or whether results are "still working." Creators at this stage sometimes speculate about what happens if you stop the medication, or whether they'll need to stay on it indefinitely. These are legitimate questions, but the answers on TikTok are frequently incomplete, anecdotal, or drawn from other users rather than clinical data.

What does the science actually show?

The SUSTAIN and STEP trial programs are the backbone of what we actually know about long-term semaglutide use. The STEP 1 trial (Wilding et al., 2021, NEJM) showed that adults on 2.4 mg weekly semaglutide lost an average of 14.9% of body weight over 68 weeks versus 2.4% on placebo. More relevant for a week-87 update is the STEP 4 trial (Rubino et al., 2021, JAMA), which found that participants who stopped semaglutide after 20 weeks regained two-thirds of their lost weight within one year. That's a number that gets glossed over constantly on social media. The SELECT trial (Lincoff et al., 2023, NEJM) extended the picture further, showing cardiovascular benefit in non-diabetic adults with obesity over a mean follow-up of 34 months. Week 87 is roughly 20 months, so this creator is in territory where real clinical data exists, and it generally supports continued use for sustained benefit.

Where does the social media noise diverge from clinical reality?

The divergence is significant in several areas. First, long-running TikTok series tend to normalize the idea that results should be linear, and week 87 creators often frame plateaus as personal failures or reasons to increase doses. Clinically, weight plateaus on GLP-1 receptor agonists are expected and well-documented. Second, there is a persistent misconception that Ozempic and Wegovy are interchangeable products. They are not. Ozempic is approved at up to 2 mg for type 2 diabetes; Wegovy delivers 2.4 mg weekly specifically for chronic weight management. Using Ozempic off-label for weight loss means the approved weight-loss dose may not be what the creator is actually taking. Third, anecdotal side effect timelines shared in these videos frequently diverge from trial data. Nausea rates in the STEP trials peaked early and subsided; if a creator is still reporting significant nausea at week 87, that warrants a clinical conversation, not a TikTok comment thread.

What should you actually know?

If you are watching week-87 content and considering semaglutide yourself, the most important clinical reality is this: long-term use appears to be what sustains results. The STEP 4 data is not a scare story; it is a pharmacological fact about how GLP-1 agonists work. Appetite suppression and metabolic effects diminish when the drug is discontinued. That does not mean it is dangerous or addictive; it means obesity is a chronic condition requiring ongoing management, which is exactly how the FDA frames the approved indication for Wegovy. Cost and access are real barriers that TikTok creators rarely address with accuracy. Compounded semaglutide is not equivalent to brand-name Wegovy or Ozempic, and patients sourcing it outside of regulated channels take on meaningful risks including dosing variability and lack of pharmaceutical oversight. A telehealth provider with proper prescribing protocols is the appropriate starting point, not a comment section.